(Q46087786)

19 December 2017

title

Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance (English)

1 reference

19 December 2017

main subject

endometrial hyperplasia

1 reference

Xiaojun Chen

1

1 reference

19 December 2017

Zhenbo Zhang

2

1 reference

19 December 2017

Youji Feng

3

1 reference

19 December 2017

Oluwole Fadare

4

1 reference

19 December 2017

Jun Wang

5

1 reference

19 December 2017

Zhihong Ai

6

1 reference

19 December 2017

Hongyan Jin

7

1 reference

19 December 2017

Chao Gu

8

1 reference

19 December 2017

Wenxin Zheng

9

1 reference

19 December 2017

publication date

13 March 2009

1 reference

19 December 2017

published in

Modern Pathology

1 reference

19 December 2017

volume

22

1 reference

19 December 2017

issue

5

1 reference

19 December 2017

page(s)

699-708

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.25

exact match

0 references

cites work

Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

TNFalpha expression in hyperplastic endometrium

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Apoptosis may be an early event of progestin therapy for endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Survivin, cancer networks and pathway-directed drug discovery.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Survivin: a promising biomarker for detection and prognosis of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Expression of survivin and Bcl-2 in the normal human endometrium

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Survivin study: an update of "what is the next wave"?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Role of the Survivin gene in pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Endometrial hyperplasia: a review

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Survivin mediates resistance to antiandrogen therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Diabetes and risk of endometrial cancer: a population-based prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Role of the insulin-like growth factor family in cancer development and progression

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.25

7 January 2021

10.1038/MODPATHOL.2009.25

Identifiers

DOI

1 reference

19 December 2017

release_rk4q7ccnu5bnfikxjf4a6fzmuy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rk4q7ccnu5bnfikxjf4a6fzmuy

24 November 2022

mapped directly with Wikidata item

PubMed ID

19287462

1 reference

19 December 2017